One-sentence summary of key findings: BRVE is the newly listed ticker (NASDAQ) for Braveheart Bio, Inc., a clinical-stage biopharmaceutical company developing a next-generation oral cardiac myosin inhibitor (BHB-1893/HRS-1893) for hypertrophic cardiomyopathy (HCM), which completed an upsized IPO on August 6, 2026, raising $382.5 million at $18 per share following positive Phase 2 data from its Hengrui Pharma partnership.[[1]](https://www.biospace.com/press-releases/braveheart-bio-announces-pricing-of-upsized-initial-public-offering)[[2]](https://www.biopharmadive.com/news/braveheart-cardiac-drugs-ipo-pricing/826973/)
Fact: Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Its lead candidate is BHB-1893 (also referred to as HRS-1893), an oral small-molecule cardiac myosin inhibitor (CMI) for obstructive and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California. It has approximately 30 employees.[[3]](https://finance.yahoo.com/quote/BRVE/)[[4]](https://stockanalysis.com/stocks/brve/)
Interpretation: The company positions itself as a potential “best-in-class” challenger in the HCM space by aiming for improved speed of onset, depth of response, systolic safety, and reversibility compared to existing treatments.
Uncertainty/Assumption flag: As a pre-commercial clinical-stage biotech, all pipeline success, regulatory approvals, and commercialization are highly uncertain and dependent on future clinical trial outcomes (no approved products yet).
More information: Company Website | Investor Relations
Data limitation: Extremely short corporate history as a public entity (trading began August 6, 2026); pre-IPO details rely on press releases and SEC filings.
More information: SEC S-1 Filing
More information: Yahoo Finance BRVE Page | Company News
Fact: Trading began August 6, 2026 (IPO day). Pre-IPO market cap estimates around $1.13 billion post-pricing. No long-term performance history available.[[4]](https://stockanalysis.com/stocks/brve/)
Uncertainty flag & data limitation: All post-IPO trading data, volume, and performance metrics are not yet available or are preliminary (day 1 only). Do not rely on any intraday surge for long-term assessment. Guidelines prohibit displaying current stock price.
| Metric | Value | Notes |
|---|---|---|
| Net Income (TTM) | -$80.23 million | Typical for clinical-stage biotech (R&D heavy) |
| Revenue (TTM) | N/A or minimal | No commercial products |
| Total Cash (most recent quarter) | ~$80.58 million (pre-IPO); significantly higher post-IPO | IPO added substantial runway |
| Total Debt/Equity | 0.93% | Low leverage |
| Profit Margin | 0.00% | Pre-revenue stage |
Interpretation: Strong cash position post-IPO provides multi-year runway for Phase 3 development, but ongoing losses are expected until potential commercialization.
More information: Yahoo Finance Financials | Stock Analysis Profile
Fact: No major Wall Street firm coverage or consensus ratings reported as of IPO date (typical for very recent listings). Seeking Alpha author ratings page exists for BRVE.[[8]](https://seekingalpha.com/symbol/BRVE/ratings/author-ratings)
Uncertainty & limitation: Analyst coverage is expected to emerge over time but is currently absent or limited to pre-IPO research/hype. Any early ratings should be viewed skeptically due to lack of public trading history and clinical-stage risks. No price targets available.
More information: Seeking Alpha BRVE Ratings
Uncertainty: Commercial success depends entirely on clinical/regulatory outcomes and market adoption; no revenue from customers yet.
| Competitor | Key Product/Approach | Status |
|---|---|---|
| Bristol Myers Squibb | Camzyos (mavacamten) - cardiac myosin inhibitor | Approved/marketed for obstructive HCM |
| Cytokinetics | Cardiac myosin inhibitors in development | Clinical-stage for HCM |
| Others (various biotechs) | Alternative HCM therapies | Varies |
Interpretation: Braveheart aims to differentiate on attributes like onset speed and safety profile versus established players like BMS.
More information: Company pipeline comparisons on braveheart.bio